National Health (Pharmaceutical Benefits - Early Supply) Amendment Instrument 2014 (No. 2) - specification under subsection 84AAA(2) (No. PB 34 of 2014)

Link to law: https://www.comlaw.gov.au/Details/F2014L00402

 
PB 34 of 2014
National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 2) – specification under subsection 84AAA(2)
 
National Health Act 1953
 
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated                            9 April 2014
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
 
 
 
___________________________________________________________________________
 
 
Amendment determination – Pharmaceutical Benefits – Early Supply
 
 
1          Name of Instrument
 
(1)           This Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 2) – specification under subsection 84AAA(2).
 
(2)           This Instrument may also be cited as PB 34 of 2014.
 
 
2          Commencement
 
This Instrument commences on 1 May 2014.
 
3          Amendment of PB 30 of 2009
 
Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) (PB 30 of 2009).
 
Schedule 1        Amendments
 
[1]        Schedule 1, column headings
(a)   omit:        Form (strength, type, size, etc.)            substitute        Form
(b)   omit:        Maximum repeats              substitute        Maximum number of repeats
[2]        Schedule 1, entry for Amlodipine
omit:
 
Tablet 5 mg (as maleate)
Oral
30
5
 

 
Tablet 10 mg (as maleate)
Oral
30
5
 

[3]        Schedule 1, entry for Dabigatran
omit from the column headed “Listed drug”:         Dabigatran            substitute:     Dabigatran etexilate
[4]        Schedule 1, entry for Nilotinib in the form Capsule 200 mg (as hydrochloride monohydrate)
omit from the column headed “Listed drug”:         Nilotinib               [name of listed drug exists]
[5]        Schedule 1, omit entry for Pergolide
[6]        Schedule 1, entry for Rivaroxaban
omit from the column headed “Form”:                    Tablet, 15mg           substitute:      Tablet 15 mg
[7]        Schedule 1, after entry for Salcatonin in the form Injection 100 I.U. in 1 mL ampoule
insert:
Sapropterin
Tablet (soluble) containing sapropterin hydrochloride 100 mg
Oral
180
5
 
[8]        Schedule 1, entry for Verapamil
omit:
 
Tablet containing verapamil hydrochloride 120 mg
Oral
100
5
 
 
Read Entire Law on www.comlaw.gov.au